PRAX

Praxis Precision Medicines recently outlined a busy November calendar, with third quarter 2026 results released on November 9 and an Investor Day on November 12 covering commercial plans for ulixacaltamide and relutrigine, alongside slots at several major…

Praxis Precision Medicines has delivered a very large 3 year share price gain, yet recent pullbacks and a shifting business profile now put the spotlight on a more basic question.

Two FDA applications advance as cash runway extends into 2028.

Praxis Precision Medicines reported its second-quarter 2026 results, posting a net loss of US$83.72 million and basic loss per share from continuing operations of US$2.87, while reaffirming its focus on central nervous system therapies.

Moby summary of Praxis Precision Medicines, Inc.'s Q2 2026 earnings call

Praxis Precision Medicines (NASDAQ:PRAX) said it is preparing for potential commercial launches of ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related developmental and epileptic encephalopathies, or DEEs, as both new drug applications remain under FDA review.

Praxis Precision Medicines Inc (PRAX) reports strong regulatory progress for ulixacaltamide and relutrigine, while addressing the POWER1 miss and preparing for commercial launches.

Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027 Mid-cycle meeting completed for relutrigine; FDA…

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc.

BOSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc.

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 affordable biotech stocks to buy right now. On July 7, Praxis Precision Medicines Inc.